Anika Therapeutics (ANIK) EBT Margin (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of EBT Margin data on file, last reported at 16.28% in Q1 2026.

• On a quarterly basis, EBT Margin fell 150.0% year-over-year to 16.28% in Q1 2026; TTM through Mar 2026 was 8.82%, a 367.0% decrease from a year earlier, with the FY2025 full-year figure at 8.25%, down 485.0% from the prior year.
• EBT Margin for Q1 2026 stood at 16.28%, down from 2.5% in the prior quarter.
• Over the last five years, EBT Margin for ANIK reached as high as 2.5% in Q4 2025 and fell as low as 846.64% in Q4 2023.
• Historically, EBT Margin has averaged 93.92% across 5 years, with a median of 10.11% in 2022.
• Across the five-year window, EBT Margin slumped 55902 bps in 2022 and jumped 84247 bps in 2024, its largest moves.
• Year by year, EBT Margin stood at 598.46% in 2022, then sank by 41 bps to 846.64% in 2023, then surged by 100 bps to 4.17% in 2024, then soared by 160 bps to 2.5% in 2025, then slumped by 752 bps to 16.28% in 2026.
• Per Business Quant data, the three most recent EBT Margin figures were 16.28% in Q1 2026, 2.5% in Q4 2025, and 8.04% in Q3 2025.